Incidence of recurrent fungal keratitis after primary keratoplasty and visual outcome and prognosis after intervention for the recurrence

Yuerong Gong, MS\textsuperscript{ab,}\textsuperscript{*}, Meng Xin, MD\textsuperscript{c}

Abstract

There are no standardized protocols or guidelines for the treatment of recurrent fungal keratitis after therapeutic keratoplasty. This study aimed to investigate the incidence of recurrent fungal keratitis after the primary keratoplasty and the visual outcome and prognosis after intervention for the recurrence.

This was a retrospective study. Patients with recurrent fungal keratitis after lamellar keratoplasty (LK) or penetrating keratoplasty (PK) were treated with different antifungal regimens at Shandong Eye Hospital and Qingdao Eye Hospital between January 2004 and December 2015. The operative techniques included PK, focal excision, tectonic keratoplasty with a patch graft, lensectomy and vitrectomy, and combined operation. Patients were followed at 1, 2, and 3 months, and then every 6 months after surgery for 2 years. Best corrected visual acuity was assessed and recurrence was recorded. Good prognosis was defined as the presence of visual acuity.

Fungal keratitis recurred in 112 of 1448 patients (112/1448, 7.7%) treated initially with PK or LK. The good prognosis rates for different sites of recurrent fungal keratitis were: overall, 93 of 112 (83.0%); recipient bed, 64 of 69 (92.8%); anterior segment, 14 of 14 (100%); posterior segment, 10 of 16 (62.5%); and atypical, 5 of 13 (38.5%). There was no significant difference in the timing of recurrence between the good and poor prognosis groups ($P = .518$). Recurrence rates were similar between patients with PK (8.8%) and those with LK (6.0%; $P > .05$), but the good prognosis rate in patients with post-LK recurrence (96.8%) was higher than that in patients with post-PK recurrence (77.8%, $P = .017$).

Individualized treatment according to recurrent sites of fungal keratitis can achieve a good prognosis in most patients.

Abbreviations: BCVA = best corrected visual acuity, LK = lamellar keratoplasty, PK = penetrating keratoplasty, SD = standard deviation.

Keywords: lamellar keratoplasty, penetrating keratoplasty, Recurrent Fungal Keratitis

1. Introduction

In China, fungal keratitis is the most common cause of blindness among patients with infectious corneal diseases.\textsuperscript{[1–3]} A variety of pharmacological agents are available for the treatment of fungal keratitis, which include polyenes (eg, amphotericin B) and azoles (eg, ketoconazole and voriconazole),\textsuperscript{[4–8]} but not all cases of fungal keratitis respond to pharmacotherapy. Therefore, therapeutic keratoplasty retains an important role in the management of progressive fungal keratitis refractory to medical treatment.\textsuperscript{[9–14]} Nevertheless, keratitis can still recur in 10% to 15% of patients treated with therapeutic keratoplasty.\textsuperscript{[9,10,13–17]} A variety of therapeutic approaches have been used to manage the recurrence of fungal keratitis after therapeutic keratoplasty, which include antifungal medications (fluconazole or voriconazole) administered as eye drops or through intravenous, subconjunctival, or intracameral injections, repeat keratoplasty, and evisceration.\textsuperscript{[9,10,15–18]} Currently, there are no standardized protocols or guidelines for the treatment of recurrent corneal fungal infection after therapeutic keratoplasty. Failure to recognize recurrent fungal keratitis in its early stages or to take an effective treatment measure in a timely manner can result in suboptimal therapy and even eye loss. The selection of an appropriate intervention is further complicated by the possibility that different sites of recurrent keratitis may need different treatment approaches. Therefore, research is needed to identify reasonable and effective treatment strategies for the recurrence of fungal keratitis after therapeutic keratoplasty, as well as the factors associated with recurrence and prognosis after treatments.

Therefore, the aim of the present study was to investigate the incidence of recurrent fungal keratitis after the primary keratoplasty and the visual outcome and prognosis after intervention for the recurrence. This study retrospectively evaluated the effects of
individualized treatment regimens on the recurrence of fungal keratitis after therapeutic keratoplasty in patients at the Shandong Eye Hospital and Qingdao Eye Hospital (China).

2. Materials and methods

2.1. Patients

This was a retrospective study. Patients with recurrent fungal keratitis after initial lamellar keratoplasty (LK) or penetrating keratoplasty (PK) for fungal keratitis were treated at Shandong Eye Hospital and Qingdao Eye Hospital between January 2004 and December 2013, and included in this study. This study was approved by the Ethics Committee of the Shandong Eye Hospital and Qingdao Eye Hospital.

Recurrent fungal keratitis was diagnosed by clinical examination (eg, gray-white invasive lesion of the recipient bed, mushroom-shaped pus mass at the pupillary zone, pus mass at the pupillary zone, and/or hypopyon reappearance) or confocal microscopy that was used to confirm the presence of fungal hyphae deep in the cornea, as previously described.[16] Etiologic diagnosis was based on fungal hyphae-positive smears or fungal culture from specimens obtained during secondary surgery.

The inclusion criteria were: initial keratoplasty for fungal keratitis; recurrent fungal keratitis confirmed by clinical examination, and/or confocal microscopy, and/or smears/cultures of corneal tissue, aqueous humor or vitreous body samples; 1 eye involvement. Those with the coexistence of other complications of keratoplasty were excluded.

**Table 1**

| Types       | Manifestations under slit lamp                                                                 | Association between manifestations and the recurrence site                                                                 | Strategies for individualized treatment                                                                 |
|-------------|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| RBC         | Gray-white invasive lesion of the recipient bed, including the donor/host junction.            | The gray-white invasive lesion of the recipient bed is the initial recurrence site.                                      | A. PK with the same diameter of LK for deep RBC under the lamellar graft after initial LK.               |
|             | Some patients may have purulent exudate at the donor/host junction, or additional hypopyon.    |                                                                                                                          | B. Corneal lesion resection + bulbar conjunctiva flap covering for superficial peripheral RBC after initial LK. |
| ACR         | Mushroom-shaped pus mass at the anterior chamber angle or the surface of the iris               | The covered mushroom-shaped pus mass is the initial recurrence site.                                                     | C. PK with expanded diameter of LK for deep peripheral RBC after initial LK.                            |
| PSR         | Pus mass at the pupillary zone.                                                                | The pus mass at the pupillary zone suggests that the initial recurrence site is at the posterior segment. The pus from the posterior segment crosses the pupil into the anterior chamber and forms a pus mass at the pupillary zone. | D. Expanded diameter of PK for RBC involving the corneal graft after initial PK.                        |
| AR          | Hypopyon without invasive lesion of the recipient bed, mushroom-shaped pus mass, or pus mass at the pupillary zone. | Hypopyon is not the site of the initial recurrence. The initial recurrence site can only be determined after hypopyon lavage and exploration. | E. Corneal lesion resection for RBC ≤2 mm and not involving the corneal graft after initial PK; expanded diameter of PK for uncontrolled recurrence after resection. |
|             |                                                                                                 |                                                                                                                          | F. Expanded diameter of PK for RBC >2 mm and not involving the sclera after initial PK.                  |
|             |                                                                                                 |                                                                                                                          | G. PK with patch graft for RBC >2 mm involving slightly the sclera after initial PK.                    |
|             |                                                                                                 |                                                                                                                          | H. Encleavage or evisceration for widespread infection of the sclera after initial PK.                  |

RBC = recipient bed recurrence, ACR = anterior chamber recurrence, PSR = posterior segment recurrence, AR = atypical recurrence, LK = lamellar keratoplasty, PK = penetrating keratoplasty.

2.2. Indications for the initial keratoplasty

The indication for LK was that the infection did not involve the descemet membrane. The indications for PK were that the infection invaded the entire cornea; the descemet membrane and endothelium layer; or there was corneal perforation.

2.3. Postoperative medical therapy after initial therapeutic keratoplasty

Postoperative management of patients after initial therapeutic keratoplasty (for the first presentation of fungal keratitis) was performed as previously described.[16] Oral fluconazole was administered 1 day before keratoplasty and lasted for 21 days. Postoperatively, 0.5% fluconazole, 0.25% amphotericin B, or 5% natamycin were administered topically 4 times daily for 2 weeks, and subsequently tapered. Antifungal drops and nonsteroidal anti-inflammatory drops were also administered 4 times daily. If there were no signs of recurrence 2 weeks after surgery, 0.02% fluorometholone was topically administered twice daily for 1 week, and then changed to 4 times daily.

2.4. Classification of recurrent fungal keratitis

Recurrent fungal keratitis after therapeutic keratoplasty was classified based on the clinical features: recipient bed recurrence, anterior chamber recurrence, posterior segment recurrence, and atypical recurrence (Table 1). Recurrence of fungal keratitis was also classified as early recurrence (occurring within 8 days after initial keratoplasty) and late recurrence (occurring more than 8 days after initial keratoplasty).

**Table 1**

| Types       | Manifestations under slit lamp                                                                 | Association between manifestations and the recurrence site                                                                 | Strategies for individualized treatment                                                                 |
|-------------|------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| RBC         | Gray-white invasive lesion of the recipient bed, including the donor/host junction.            | The gray-white invasive lesion of the recipient bed is the initial recurrence site.                                      | A. PK with the same diameter of LK for deep RBC under the lamellar graft after initial LK.               |
|             | Some patients may have purulent exudate at the donor/host junction, or additional hypopyon.    |                                                                                                                          | B. Corneal lesion resection + bulbar conjunctiva flap covering for superficial peripheral RBC after initial LK. |
| ACR         | Mushroom-shaped pus mass at the anterior chamber angle or the surface of the iris               | The covered mushroom-shaped pus mass is the initial recurrence site.                                                     | C. PK with expanded diameter of LK for deep peripheral RBC after initial LK.                            |
| PSR         | Pus mass at the pupillary zone.                                                                | The pus mass at the pupillary zone suggests that the initial recurrence site is at the posterior segment. The pus from the posterior segment crosses the pupil into the anterior chamber and forms a pus mass at the pupillary zone. | D. Expanded diameter of PK for RBC involving the corneal graft after initial PK.                        |
| AR          | Hypopyon without invasive lesion of the recipient bed, mushroom-shaped pus mass, or pus mass at the pupillary zone. | Hypopyon is not the site of the initial recurrence. The initial recurrence site can only be determined after hypopyon lavage and exploration. | E. Corneal lesion resection for RBC ≤2 mm and not involving the corneal graft after initial PK; expanded diameter of PK for uncontrolled recurrence after resection. |
|             |                                                                                                 |                                                                                                                          | F. Expanded diameter of PK for RBC >2 mm and not involving the sclera after initial PK.                  |
|             |                                                                                                 |                                                                                                                          | G. PK with patch graft for RBC >2 mm involving slightly the sclera after initial PK.                    |
|             |                                                                                                 |                                                                                                                          | H. Encleavage or evisceration for widespread infection of the sclera after initial PK.                  |

2.2. Indications for the initial keratoplasty

The indication for LK was that the infection did not involve the descemet membrane. The indications for PK were that the infection invaded the entire cornea; the descemet membrane and endothelium layer; or there was corneal perforation.

2.3. Postoperative medical therapy after initial therapeutic keratoplasty

Postoperative management of patients after initial therapeutic keratoplasty (for the first presentation of fungal keratitis) was performed as previously described.[16] Oral fluconazole was administered 1 day before keratoplasty and lasted for 21 days. Postoperatively, 0.5% fluconazole, 0.25% amphotericin B, or 5% natamycin were administered topically 4 times daily for 2 weeks, and subsequently tapered. Antifungal drops and nonsteroidal anti-inflammatory drops were also administered 4 times daily. If there were no signs of recurrence 2 weeks after surgery, 0.02% fluorometholone was topically administered twice daily for 1 week, and then changed to 4 times daily.

2.4. Classification of recurrent fungal keratitis

Recurrent fungal keratitis after therapeutic keratoplasty was classified based on the clinical features: recipient bed recurrence, anterior chamber recurrence, posterior segment recurrence, and atypical recurrence (Table 1). Recurrence of fungal keratitis was also classified as early recurrence (occurring within 8 days after
therapeutic keratoplasty) or late recurrence (occurring from 2 weeks after therapeutic keratoplasty).

2.5. Individualized treatment for recurrent fungal keratitis

The general treatment for recurrent fungal infection was aggressive medical therapy. All patients received antifungal drugs both topically (0.5% fluconazole or voriconazole drops every 15 minutes combined with 0.25% amphotericin B or 5% natamycin drops once every hour) and subconjunctivally (injections of 3-mg fluconazole or voriconazole once or twice daily). For some patients with recipient bed recurrence, intrastromal injections of antifungal drugs (1-mg fluconazole or voriconazole once or twice daily) were initially conducted. Individualized treatment was conducted if the general treatment was ineffective after 3 to 5 days of treatment. The details of the individualized treatment for the different types of recurrence are shown in Table 1.

2.6. Follow-up

All patients were followed at 1, 2, and 3 months after discharge, and then every 6 months for 2 years. Best corrected visual acuity (BCVA) was assessed using comprehensive refractometry and vision chart. Recurrence was also recorded.

2.7. Treatment evaluation

For the analysis of treatment effect, good prognosis was defined as the presence of visual acuity. Poor prognosis was defined as failure in infection control with evisceration or enucleation of the eyeball or termination of treatment owing to ineffectiveness.

2.8. Statistical analysis

Statistical comparisons were conducted using SPSS 17.0 (IBM, Armonk, NY). Continuous variables are expressed as means ± standard deviations (SD) and were compared between groups using the Student t test. Categorical variables are presented as frequency and percentage and were compared between groups using the χ² test or Fisher exact test. Two-sided P values <.05 were considered statistically significant.

3. Results

3.1. General characteristics of the patients included in the analysis

During the study period, 1448 patients with fungal keratitis that could not be controlled medically underwent PK (937/1448, 64.7%) or LK (511/1448, 35.3%). As shown in Table 2, 1325 (91.5%) of the 1448 patients were positive for fungal culture.

Recurrent fungal keratitis occurred in 112 (7.7%) of the 1448 patients treated with therapeutic keratoplasty. Among the 112 patients with recurrence, 99 received etiologic diagnosis (by identifying fungal hyphae in the smears or fungal growth in culture; Table 2), 10 were diagnosed by confocal microscopy (the presence of fungal hyphae deep in the cornea), and 3 were diagnosed by clinical manifestations. These 112 patients (including 81 post-PK and 31 post-LK) were included in the final analysis. Patient age ranged from 12 to 80 years (mean of 49.1 years). There were 64 men and 48 women. Seven (6.3%) of the 112 patients had treatment terminated because of ineffectiveness and 12 (10.7%) of the 112 patients underwent evisceration or enucleation of the eyeball because of uncontrolable infection. The overall good prognosis rate for the treatment of recurrent fungal keratitis was 83.0% (93/112). As shown in Table 2, there was no significant difference in the microbiological results between the fungal keratitis group (n=1448) and the recurrence group (n=112). There was also no significant difference in the microbiological results between the good prognosis group (n=93) and the poor prognosis group (n=19).

3.2. Prognosis of the different clinical types of fungal keratitis

The good prognosis rates of the different sites of recurrent fungal keratitis were: recipient bed recurrence, 64 of 69 (92.8%); anterior chamber recurrence, 14 of 14 (100%); posterior segment recurrence, 10 of 16 (62.5%); and atypical recurrence, 5 of 13 (38.5%) (Table 3). There was no significant difference in the timing of recurrence between the good and poor prognosis groups (P=.518).

### Table 2

| Fungus, n (%) | Fungal keratitis (n=1448) | Recurrence (n=112) | Good prognosis (n=93) | Poor prognosis (n=19) |
|---------------|--------------------------|--------------------|-----------------------|----------------------|
| Fusarium      | 905 (62.5)               | 68 (60.7)          | 55 (59.1)             | 13 (68.4)            |
| Aspergillus   | 183 (12.6)               | 19 (17.0)          | 16 (17.2)             | 3 (15.8)             |
| Alternaria    | 61 (4.2)                 | 4 (3.6)            | 4 (4.3)               | 0                    |
| Candida       | 25 (1.7)                 | 1 (0.9)            | 1 (1.1)               | 0                    |
| Penicillium   | 28 (1.9)                 | 2 (1.8)            | 2 (2.2)               | 0                    |
| Acremonium    | 22 (1.5)                 | 2 (1.8)            | 2 (2.2)               | 0                    |
| Dematiaceous hyphomycetes | 23 (1.6)               | 2 (1.8)            | 1 (1.1)               | 1 (5.3)             |
| Mycelia sterila | 20 (1.4)                 | 4 (3.6)            | 3 (3.2)               | 1 (5.3)             |
| Other funguses | 19 (1.3)                 | 2 (1.8)            | 2 (2.2)               | 0                    |
| Unidentifiable funguses | 39 (2.7)               | 3 (2.7)            | 3 (3.2)               | 0                    |
| Smears (+), culture (−) | 123 (8.5)               | 5 (4.5)            | 4 (4.3)               | 1 (5.3)             |

P<.05 for all funguses, fungal keratitis group vs recurrence group.

P<.05 for all funguses, good prognosis group vs poor prognosis group.
3.3. Comparison of prognosis between patients with recurrent fungal keratitis after LK and PK

The recurrence rates did not differ significantly between initial PK (81/937, 8.6%) and LK groups (31/511, 6.1%; \(P = .079\)), but the good prognosis rate of post-LK recurrent patients (30/31, 96.8%) was significantly higher than that of post-PK recurrent patients (63/81, 77.8%; \(P = .017\)).

The only recurrent site of fungal keratitis after LK was the recipient bed. Post-LK recurrent fungal keratitis occurred in the deep central bed in 25 of 31 patients (80.6%). All patients with deep lamellar recurrence had different degrees of anterior chamber response and 68.0% of patients (17/25) had a hypopyon or severe fibrinous effusion. Of the 31 patients with post-LK recurrent fungal keratitis, 8 (25.8%) had a good prognosis with antifungal drug therapy (including intrastromal injections and intracameral injections), 21 (67.7%) were cured by PK, and 1 (3.2%) finally required enucleation of the eyeball because of precipitously deteriorating condition.

Post-PK recurrent fungal infection occurred at various sites: recipient bed (69/81, 85.2%), anterior chamber (14/81, 17.3%), posterior segment (16/81, 19.8%), and atypical recurrence (13/81, 16.0%). After aggressive individualized treatment, 63 patients (63/81, 77.8%) had good prognosis; 7 patients (8.6%) had treatments terminated, and 11 patients (13.5%) finally required enucleation or evisceration of the eyeball. Representative cases of patients with recurrent fungal keratitis are shown in Figures 1 and 2.

3.4. BVCA after recurrent fungal infection and individualized treatment

In the good prognosis group, BVCA was well maintained during the 2 years of follow-up (Table 4).

4. Discussion

This study aimed to investigate the incidence of recurrent fungal infection after the primary surgery and the visual outcome and prognosis after intervention for the recurrence. Our findings suggest that recurrent fungal keratitis might require an individualized therapy tailored to the site of recurrent fungal keratitis, which can achieve good prognosis in the majority of patients.

In this study, the overall rate of recurrent fungal keratitis after initial therapeutic keratoplasty was 7.7% (112/1448), which is in agreement with previous reports.\[9,10,15–18\] Because of the various manifestations of recurrent fungal keratitis and the lack of systematic treatment protocols or guidelines, it remains a challenge for ophthalmologists to appropriately manage this condition. This study included 112 cases of recurrent fungal infection and provides insights into individualized treatment strategies.
infection and the treatments were tailored to the various sites of recurrence. Notably, the use of individualized treatments resulted in an overall good prognosis rate of 83.0%.

Among the 112 patients with recurrent fungal keratitis, 30 (26.8%) were successfully managed using topical, subconjunctival, intrastromal, intracameral, and/or vitreous administration of antifungal drugs, mainly voriconazole. Treatment of a small series of 25 patients with deep refractory fungal keratitis showed that intrastromal voriconazole could treat the infection in 76% of the patients.[7] However, a study of 940 patients in India showed that voriconazole was not superior to natamycin.[19] In the present study, the success rate of medical treatment was 26.8% in patients with recurrent fungal keratitis, which could be considered as low. It is possible that the fungus was resistant or was not sensitive to the drugs selected. Nevertheless, it would not be unreasonable to treat all patients initially with medical therapy and closely observe for any signs of improvement or deterioration. Nonetheless, the majority of cases of recurrence ultimately required re-operation to control the fungal infection. Therefore, if no obvious improvement is achieved after 3 to 5 days of medical therapy, operation is then the choice of treatment.

In this study, all cases of recipient bed recurrence without graft infection were successfully treated, likely because of the early identification of the infection site and timely treatment. Based on the principle that minimal interventional damage be exerted, the first choice of operation, if any, for these cases was focal excision and re-seaming of the graft-host junction. Although several patients complained of temporary astigmatism, the original regular graft could be preserved and the operative damage was small, enabling patients to recover quickly with few complications.

However, treatment is more challenging when infiltration of the corneosclera or sclera occurs.[20] In our hospital, a new
method has been used to treat corneoscleral or scleral recurrent fungal infection. A tectonic keratoplasty with a patch graft from preserved corneoscleral ring in glycerin is attempted to connect the graft-host junction of the preexisting PK. This method offers a less invasive alternative to repeat PK and allows retention of the parent PK. Moreover, this approach avoids the use of large, oversized transplants that can result in serious complications such as peripheral anterior synechia and secondary glaucoma. All patients treated with this technique in the present study achieved good tectonic stability. Although some may question the adequacy of the endothelial function in these cases, those 5 patients who received tectonic keratoplasty with a patch graft in this study were found to have no endothelial function. Nevertheless, the number of cases was small and studies with larger numbers of patients are necessary to verify the efficacy of this technique.

In cases of recipient bed recurrence that extended to the graft, resection of the lesions was often inefficient even if the recurrent lesions were small. In these patients, therapeutic PK with a large corneal graft was often necessary to control the recurrence. In this study, 7 of 8 of the cases with graft infection underwent lesion resection, and 5 of these failed. These 5 patients were ultimately successfully treated by therapeutic PK with a large corneal graft, indicating that this may be the therapy of choice when recipient bed recurrent fungal infection extends to the graft.

Anterior chamber recurrence is likely because of residual fungal foci in deep tissues at the juncture between the recipient bed and the graft. A small amount of mycelia propagates locally, forming a mushroom-shaped pus mass. Thus, a good therapeutic effect could be obtained if the recurrence was detected at an early phase and treated promptly with an effective method such as intracameral injection or lavage of antifungal drugs. In this study, about 80% cases of anterior chamber recurrences were resolved with intracameral injection or lavage with antifungal drugs after the removal of the mushroom-shaped pus mass. Fungal hyphae were detected by smear examination of the removed pus mass. The remaining anterior chamber recurrent cases were cured by anterior chamber lavage with antifungal drugs combined with recipient bed lesion excision. Intracameral injection or lavage with antifungal drugs after removing the mushroom-shaped pus mass may therefore be sufficient for most cases of anterior chamber recurrence.

When posterior segment recurrence has occurred and there is a purulent exudate covering the lens surface in the pupillary zone, the infection has already extended to the lens or anterior vitreous and sometimes even to the posterior vitreous. In these cases, treatments such as simple anterior chamber irrigation and

Table 4

| Time point, n (%) | BCVA < 0.1 | 0.1 ≤ BCVA < 0.4 | BCVA ≥ 0.4 |
|------------------|------------|------------------|------------|
| 1 mo (n=93)      | 18 (19.4)  | 45 (48.3)        | 30 (32.3)  |
| 3 mo (n=93)      | 17 (18.2)  | 47 (50.6)        | 29 (31.2)  |
| 6 mo (n=91)      | 15 (16.5)  | 49 (53.8)        | 27 (29.7)  |
| 12 mo (n=79)     | 3 (3.8)    | 54 (68.4)        | 22 (27.8)  |
| 18 mo (n=43)     | 1 (2.3)    | 30 (69.8)        | 12 (27.9)  |
| 24 mo (n=25)     | 1 (4.0)    | 20 (80.0)        | 4 (16.0)   |

BCVA = best corrected visual acuity.
injection of antifungal drugs were not effective in most cases, and lens excision combined with vitrectomy were often needed to control the recurrence. Failure to initiate effective operative treatment in a timely manner will allow the infection to progress rapidly, potentially resulting in endophthalmitis and thus an inability to save the eye. In this study, 3 patients with posterior segment recurrence had a good prognosis with multiple anterior chamber irrigations and vitreous injections of antifungal drugs; 4 cases were successfully treated with lens excision and vitrectomy surgery; 4 lost their eye; and 1 refused further treatment.

Treatment of atypical recurrent fungal keratitis was the most challenging. Given the large range of preoperative infections, the sclera was often involved, and detecting surrounding recipient bed recurrence after surgery was difficult. This type of recurrence lacks targeted therapy and exhibits a poor prognosis. In this study, 5 patients underwent exploratory operations for recurrence in the recipient bed and were successfully treated. Five patients were found with widespread infections of the sclera during operation for atypical recurrent fungal keratitis and lost their eye. Therefore, we speculate that the starting point of this type of recurrence was the recipient bed. The remaining 3 patients discontinued treatment.

All cases of post-LK recurrent fungal infection occurred in the recipient bed, and most (80.6%) occurred in the deep recipient bed. All patients with deep lamellar recurrence had different degrees of anterior chamber response combined with a hypopyon or severe fibrinous effusion (17/25, 68%). PK was the optimal treatment choice, as focal excision combined with a conjunctival flap are not suitable for these cases. In this study, 67.7% (21/31) of patients with post-LK recurrence received PK that successfully treated the condition. The reasons for the good prognosis of the patients initially treated with LK could be that the infection did not break through the Descemet membrane before the intervention (which was the indication for LK) started and there was no fungus in the intraocular area.

Maintaining a good vision after the infection event is important for the long-term quality of life of the patients. In the present study, among those who had good prognosis after the treatment of recurrent fungal keratitis, adequate BCVA was maintained in most patients, which is also shown by other studies. Additional studies are necessary to determine which approach could achieve the best BCVA after treatments.

This study has some limitations. First, this was a retrospective study; hence, it cannot be excluded that selection bias or reporting bias influenced the results. Second, the number of patients with recurrent fungal keratitis was relatively small, limiting the statistical analyses and the conclusions. Third, this was a single-center study, so the results may not be generalizable to the general patient population. Nonetheless, the results provide useful information for the treatment of patients with recurrent fungal keratitis after therapeutic keratoplasty.

In conclusion, different keratoplasty approaches and different infection sites are associated with different prognoses. Recurrent fungal keratitis might require an individualized therapy tailored to the site of recurrent fungal keratitis, such that good prognosis can be achieved in the majority of patients with adequate BCVA. Further research is needed to confirm and expand the findings of the present study, with the aim of developing a standardized protocol for the management of recurrent fungal keratitis after therapeutic keratoplasty.

Author contributions

Investigation: Yuerong Gong, Meng Xin.
Methodology: Yuerong Gong, Meng Xin.
Writing – original draft: Yuerong Gong.

References

[1] Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ 2001;79:214–21.
[2] Song X, Xie L, Tan X, et al. A multi-center, cross-sectional study on the burden of infectious keratitis in China. PLoS One 2014;9:e113843.
[3] Cao J, Yang Y, Yang W, et al. Prevalence of infectious keratitis in Central China. BMC Ophthalmol 2014;14:43.
[4] Sauer A, Letscher-Bru V, Speeg-Schätz C, et al. In vitro efficacy of antifungal treatment using riboflavin/UV-A (365 nm) combination and amphotericin B. Invest Ophthalmol Vis Sci 2010;51:3950–3.
[5] Carrasco MA, Genesoni G. Treatment of severe fungal keratitis with subconjunctival amphotericin B. Cornea 2011;30:608–11.
[6] You X, Li J, Li S, et al. Effects of lamellar keratectomy and intrastromal injection of 0.2% fluconazole on fungal keratitis. J Ophthalmol 2015;2015:656027.
[7] Kalaselvi G, Narayana S, Krishnan T, et al. Intrastromal voriconazole for deep recalcitrant fungal keratitis: a case series. Br J Ophthalmol 2015;99:195–8.
[8] Lekhanont K, Nonpassomporn M, Nimvorapun N, et al. Treatment with intrastromal and intracameral voriconazole in 2 eyes with Lasiodiplodia theobromae keratitis: case reports. Medicine (Baltimore) 2015;94:e541.
[9] Ti SE, Scott JA, Janardhanan P, et al. Therapeutic keratoplasty for advanced suppurative keratitis. Am J Ophthalmol 2007;143:755–62.
[10] Anshu A, Parthasarathy A, Mehta JS, et al. Outcomes of therapeutic deep lamellar keratoplasty and penetrating keratoplasty for advanced infectious keratitis: a comparative study. Ophthalmology 2009;116:615–23.
[11] Sharma N, Jain M, Sehra SV, et al. Outcomes of therapeutic penetrating keratoplasty from a tertiary eye care centre in northern India. Cornea 2014;33:114–8.
[12] Sharma N, Sachdev R, Jhanji V, et al. Therapeutic keratoplasty for microbial keratitis. Curr Opin Ophthalmol 2010;21:293–300.
[13] Barut Selver O, Egrilmez S, Palamar M, et al. Therapeutic corneal transplant for fungal keratitis refractory to medical therapy. Exp Clin Transplant 2015;1:335–9.
[14] Liu Y, Jia H, Shi X, et al. Minimal trephination penetrating keratoplasty for severe fungal keratitis complicated with hypopyon. Can J Ophthalmol 2013;48:529–34.
[15] Rogers GM, Goins KM, Suphin JE, et al. Outcomes of treatment of fungal keratitis at the University of Iowa Hospitals and Clinics: a 10-year retrospective analysis. Cornea 2013;32:1131–6.
[16] Shi W, Wang T, Xie L, et al. Risk factors, clinical features, and outcomes of recurrent fungal keratitis after corneal transplantation. Ophthalmology 2010;117:890–6.
[17] Deng XX, Kamal KM, Hollander DA. The use of voriconazole in the management of post-penetrating keratoplasty Paecilomyces keratitis. J Ocul Pharmacol Ther 2009;25:175–7.
[18] Bajracharya L, Gurung R. Outcome of therapeutic penetrating keratoplasty in a tertiary eye care center in Nepal. Clin Ophthalmol 2015;9:2289–304.
[19] Praina NV, Krishnan T, Mascaréns J, et al. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. JAMA Ophthalmol 2013;131:422–9.
[20] McLintock CA, Lee GA, Atkinson G. Management of recurrent Paecilomyces lilacinus keratitis. Clin Exp Optom 2013;96:343–5.
[21] Deng SX, Hollander DA. The use of voriconazole in the management of post-penetrating keratoplasty Paecilomyces keratitis. J Ocul Pharmacol Ther 2009;25:175–7.
[22] Ansari Z, Miller D, Galor A. Current thoughts in fungal keratitis: diagnostic and treatment. Curr Fungal Infect Rep 2013;7:209–18.
[23] Roy Y, Sun Z, Chen Y, et al. Corneal debridement combined with intrastromal voriconazole for recalcitrant fungal keratitis. J Ophthalmol 2018;2018:1875627.
[24] Zhang MC, Liu X, Yin Y, et al. Lamellar keratoplasty treatment of fungal corneal ulcers with acellular porcine corneal stroma. Am J Transplant 2015;15:1068–75.